In cancer, SUMOylation influences tumor initiation, proliferation, metastasis, and therapy resistance by modulating central signaling pathways such as Wnt/β-catenin, NF-κB, and p53 (Lin et al., 2017). This evidence concerns the gene NFKB1 and neoplasm.